GLP-1 Medications and PCOS: What Women with Polycystic Ovary Syndrome Need to Know
If you decide to start
Compounded semaglutide $169/month · tirzepatide $219/month
One flat price at every prescribed dose. No membership fee. Medication and discreet shipping included if prescribed.
PCOS and weight-management treatment
PCOS is a common condition that can involve irregular ovulation, androgen-related symptoms and metabolic problems. Insulin resistance is common, including in some people without overweight. Weight-management treatment may be considered when clinically indicated; PCOS alone does not establish suitability for a particular medicine.
What the clinical evidence shows
GLP-1 medications are not FDA-approved specifically for PCOS treatment. Small studies and clinical experience suggest possible benefits, including weight loss in women with PCOS-related obesity, improvement in insulin sensitivity, lower androgen levels in some women, more regular menstrual cycles in a subset, and possible improvement in ovulation rates. These are possible effects, not expected outcomes. Larger, dedicated trials are needed.
The 2023 international PCOS guideline considers anti-obesity medicines for weight management when otherwise appropriate, but recommends their use specifically to improve reproductive outcomes only in research settings. That is a narrower recommendation than using these medicines for general weight management in PCOS, and the guideline does not name tirzepatide specifically.
Fertility considerations
Pregnancy can occur during weight-management treatment, including when periods have previously been irregular. GLP-1 medicines are not established fertility treatments. Discuss contraception and pregnancy plans before treatment. Tirzepatide used for weight management should be stopped when pregnancy is recognized. Weight loss offers no benefit during pregnancy, so contact your prescriber promptly if pregnancy occurs or is suspected.
If you use birth control pills, tirzepatide can reduce their effectiveness. The US prescribing information advises switching to a non-oral contraceptive or adding a barrier method, such as condoms, for 4 weeks after starting and for 4 weeks after every dose increase. Hormonal contraception that is not taken by mouth is not expected to be affected by tirzepatide’s effect on stomach emptying. The details are in our guide to GLP-1 treatment and birth control.
The stopping interval before a planned pregnancy differs by medicine, and the US Zepbound label does not specify a preconception interval. The US semaglutide label advises stopping at least 2 months before planned pregnancy. UK guidance advises stopping tirzepatide at least 1 month beforehand. Plan this with your prescriber rather than applying one interval to every GLP-1 medicine.
PCOS-specific treatment considerations
- Weight-loss response varies. Review progress and side effects with your clinician.
- Menstrual changes may occur — some people experience cycle regulation while others note temporary irregularity as hormones shift.
- Other medicines — Tell your prescriber about metformin, contraception and all other medicines. A clinician should review the combination and any oral-medicine absorption concerns.
- Hair and skin — Acne, excess hair growth and scalp hair loss have different causes and may require separate care. Improvement in acne or excess hair is not guaranteed; hair loss is also a reported adverse reaction to tirzepatide.
Ready to take the next step?
Discuss PCOS and GLP-1 with a providerFrequently asked questions
No. GLP-1 medications are approved for weight loss and/or diabetes, and PCOS is not a labeled indication. A provider may prescribe when weight management is medically indicated and BMI criteria are met. The 2023 international PCOS guideline supports anti-obesity medicines for weight management when otherwise appropriate, but recommends their use specifically to improve reproductive outcomes only in research settings.
Weight loss and improved insulin sensitivity may contribute to more regular cycles in some people with PCOS. Some people report more regular cycles, but this is not guaranteed and regular trials in PCOS are limited.
Plan this with your prescriber before you try to conceive. Tirzepatide used for weight management should be stopped when pregnancy is recognized, and it is not an established fertility treatment. The US Zepbound label does not specify a preconception interval, the US semaglutide label advises stopping at least 2 months before a planned pregnancy, and UK guidance advises at least 1 month for tirzepatide. If you use birth control pills, tirzepatide also requires a non-oral method or an added barrier method for 4 weeks after starting and after each dose increase.
Tell your prescriber about metformin, contraception and all other medicines you take. A clinician should review the combination and any oral-medicine absorption concerns before you start. Do not assume every combination is automatically safe, and do not stop metformin on your own.
Sources
This guide is published by Surfbound Health (Organization). It is educational content, not medical advice, and it does not replace an individual evaluation by a licensed provider.
Sources
- Zepbound (tirzepatide) prescribing information — current version, including section 12.3 (drug interactions)
- Wegovy (semaglutide) prescribing information — current version
- UK MHRA: GLP-1 medicines for weight loss and diabetes — what you need to know (preconception interval for tirzepatide)
- 2023 International Evidence-based Guideline for the Assessment and Management of PCOS
Want more evidence-based health research from Surfbound?
Add Surfbound as a Preferred Source on Google